This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.57% and 2.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
by Zacks Equity Research
Exact Sciences presents new positive evidence backing the development of an MCED test.
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
by Zacks Equity Research
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of -5% and 1.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday
by Nalak Das
We have narrowed our search to there large-cap stocks set to report results on Tuesday. These are: EXAS, DD and KGC.
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
by Zacks Equity Research
Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Perrigo to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
by Zacks Equity Research
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
by Zacks Equity Research
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI